ArticleMethods in molecular biology (Clifton, N.J.)2025
Effects of Nucleoside Modifications on mRNA Translation: Choosing the Right Modifications.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of messenger RNA (mRNA)-based vaccines against SARS-CoV-2 during the COVID-19 pandemic has driven significant advancements in mRNA-based therapeutics. Key innovations include the use of modified nucleosides and ionizable lipid nanoparticles. Modified mRNA is produced through in vitro transcription, typically employing phage T7 RNA polymerase along with a DNA template and ribonucleoside triphosphates. Chemical modifications at the 5-position of pyrimidines, (cytosine and uridine) are generally well tolerated by T7 RNA polymerase and can reduce innate immune activation, though their effects on translation vary considerably. Therefore, the nature and codon-positions of these modifications, as well as the mRNA sequence, should be considered when designing mRNA therapeutics. This chapter details the production, purification, and evaluation of translation in human cells for modified mRNA containing 5-methyluridine, 5-methoxyuridine, 5-hydroxymethyluridine, pseudouridine, N1-methylpseudouridine, or N1-ethylpseudouridine.
Indexed as
Identifiers
40877501What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.